Literature DB >> 18702915

Is there a rationale for bladder cancer screening?

Robert S Svatek, Yair Lotan.   

Abstract

Screening should decrease disease-related mortality by detecting cancer before symptoms prompt evaluation. Several characteristics of bladder cancer make screening an attractive option. Nevertheless, premature adoption of a screening program has considerable negative consequences. This article reviews the current literature regarding screening for bladder cancer and emphasizes the need for prospective, clinical trials before considering practice modification.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18702915     DOI： 10.1007/s11934-008-0058-4

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  17 in total

Review 1.  Medical screening and the value of early detection. When unwarranted faith leads to unethical recommendations.

Authors:  H M Malm
Journal:  Hastings Cent Rep       Date:  1999 Jan-Feb       Impact factor: 2.683

2.  Promoting an ethical approach to unproven screening imaging tests.

Authors:  Evelyn C Y Chan
Journal:  J Am Coll Radiol       Date:  2005-04       Impact factor: 5.532

3.  Long-term outcome of hematuria home screening for bladder cancer in men.

Authors:  Edward M Messing; Ralph Madeb; Terry Young; Kennedy W Gilchrist; Lora Bram; E Barry Greenberg; John D Wegenke; Laura Stephenson; Jason Gee; Changyong Feng
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

4.  Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Authors:  Yair Lotan; Robert S Svatek; Arthur I Sagalowsky
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

5.  Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations.

Authors:  E M Messing; T B Young; V B Hunt; K W Gilchrist; M A Newton; L L Bram; W J Hisgen; E B Greenberg; M E Kuglitsch; J D Wegenke
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

6.  Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message?

Authors:  Evelyn C Y Chan; Sally W Vernon; Frederick T O'Donnell; Chul Ahn; Anthony Greisinger; Donnie W Aga
Journal:  Am J Public Health       Date:  2003-05       Impact factor: 9.308

7.  Bladder tumours detected on screening: results at 7 years.

Authors:  M P Mayfield; P Whelan
Journal:  Br J Urol       Date:  1998-12

8.  A community study of bladder cancer screening by the detection of occult urinary bleeding.

Authors:  J P Britton; A C Dowell; P Whelan; C M Harris
Journal:  J Urol       Date:  1992-09       Impact factor: 7.450

9.  Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis.

Authors:  Mika-P Raitanen; Risto Aine; Erkki Rintala; Jukka Kallio; Pertti Rajala; Harri Juusela; Teuvo L J Tammela
Journal:  Eur Urol       Date:  2002-03       Impact factor: 20.096

10.  Hematuria home screening: repeat testing results.

Authors:  E M Messing; T B Young; V B Hunt; M A Newton; L L Bram; A Vaillancourt; W J Hisgen; E B Greenberg; M E Kuglitsch; J D Wegenke
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450
View more
  2 in total

1.  Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms.

Authors:  Eddie S Y Chan; Chi-Fai Ng; See-Ming Hou; Sidney K H Yip
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

2.  Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes.

Authors:  Ji-Qing Chen; Lucas A Salas; John K Wiencke; Devin C Koestler; Annette M Molinaro; Angeline S Andrew; John D Seigne; Margaret R Karagas; Karl T Kelsey; Brock C Christensen
Journal:  Clin Epigenetics       Date:  2022-01-21       Impact factor: 6.551
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.